Vivosim Labs, INC. annual report, FY2020

Filing and reporting period

The supplied filing is Organovo Holdings, Inc. (Nasdaq: ONVO), not Vivosim Labs, Inc. It is a Form 10-K for the fiscal year ended March 31, 2020—not a 2019 fourth-quarter filing. Figures below are in U.S. dollars unless noted.

Business context

Organovo was an early-stage biotechnology company focused on 3D bioprinted human tissues. In August 2019, it halted development of its lead liver therapeutic and other in-house pipeline programs after studies raised concerns about performance variability and durability. Its remaining operations were limited, principally to managing research collaborations and preserving its intellectual property and other assets.

Financial performance and liquidity

Revenue declined 29%, reflecting lower grant and product/service revenue as activities were reduced. Cost of revenue was $0.328 million, implying gross profit of $1.868 million and a calculated gross margin of about 85%. Research and development expense fell 64% to $5.284 million; selling, general and administrative expense rose 19% to $18.059 million, including merger-related, restructuring, and lease-exit costs. Other income was $2.767 million, including gains from asset sales and lease termination, plus interest income. No material interest-bearing debt is shown on the balance sheet; reported liabilities were accounts payable, accrued expenses, and deferred rent in the prior year.

Material changes, outlook, and risks

• Organovo sold substantially all Samsara inventory and related assets for $1.5 million in November 2019; Samsara subsequently ceased operations. It also recorded a $2.7 million restructuring charge and terminated 52 employees, about 90% of its workforce.
• The proposed merger with Tarveda Therapeutics was not approved by stockholders on April 7, 2020. After year-end, the company said it was reassessing strategic alternatives: another transaction, resuming or expanding operations, or dissolution and liquidation, which would require stockholder approval.
• Management said existing resources were expected to fund the then-current operating plan for at least 12 months. This depends on the plan and cash needs; the filing notes uncertainty about long-term financing. Meaningful revenue was not expected in the foreseeable future.
• Nasdaq had notified the company of a bid-price deficiency. A reverse split was approved by stockholders within a 20:1 to 40:1 range but remained subject to board approval; delisting remained a risk.
• COVID-19’s future effects were uncertain. The company reported no operational impact at that time but warned of possible effects on strategic transactions and any renewed development.
• The company disclosed an SEC inquiry into prior disclosures and related operations and said it was cooperating with a subpoena. It also disclosed stockholder demands and a demand letter; no loss contingency was accrued, and the company said loss amounts were not reasonably estimable.
• The independent auditor gave an unqualified opinion on the financial statements. The auditor did not audit internal control effectiveness; management reported its controls were effective.

Important facts for investors to verify

• Confirm the issuer and period: the filing is Organovo Holdings’ FY2020 10-K, not a Vivosim Labs filing or 2019 Q4 report.
• Review subsequent filings for the outcome of the Tarveda proposal, strategic-alternatives process, and any liquidation or transaction decision.
• Check current cash, operating burn, commitments, and any financing since March 31, 2020; the runway statement reflects the company’s then-current plan.
• Verify Nasdaq listing compliance and whether the proposed reverse stock split was implemented.
• Follow updates on the SEC inquiry, stockholder matters, and any resulting financial contingencies.